Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | CLPP | Q16740 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161826 | 0.89 | KCNH2 (0.45) | GRM2KCNH2RAB9ACLPPALDH1A1 | |
| SCHEMBL4153402 | 0.81 | KCNH2 (0.45) | GRM2KCNH2RAB9ACLPPALDH1A1 | |
| SCHEMBL4144321 | 0.81 | GRM2 (0.45) | GRM2KCNH2RAB9ANPC1CLPP | |
| SCHEMBL4153055 | 0.80 | GRM2 (0.51) | GRM2KCNH2RAB9ACLPPALDH1A1 | |
| SCHEMBL15866997 | 0.79 | CLPP (0.42) | GRM2KCNH2CLPPALDH1A1SMN1; SMN2 | |
| SCHEMBL4153119 | 0.78 | KCNH2 (0.42) | GRM2KCNH2RAB9ACLPPALDH1A1 | |
| SCHEMBL5998353 | 0.77 | KCNH2 (0.45) | GRM2KCNH2RAB9ANPC1CLPP | |
| SCHEMBL14260043 | 0.76 | KCNH2 (0.47) | GRM2KCNH2CLPPSMN1; SMN2KMT2A | |
| SCHEMBL4682670 | 0.75 | P2RX7 (0.43) | GRM2KCNH2RAB9ANPC1ALDH1A1 | |
| SCHEMBL2900361 | 0.75 | GAA (0.37) | GAAGRM2KCNH2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161639-A1 | Hiv integrase inhibitors | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-07-12 | — | — | US | claimed |
| US-9045486-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2015-06-02 | — | — | US | disclosed |
| US-9045486-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2015-06-02 | — | — | US | disclosed |
| WO-2014108406-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
| US-20090099168-A1 | HIV Integrase inhibitors | DONGHI MONICA | 2009-04-16 | — | — | US | disclosed |
| US-20090099168-A1 | HIV Integrase inhibitors | DONGHI MONICA | 2009-04-16 | — | — | US | disclosed |
| US-20090099168-A1 | HIV Integrase inhibitors | DONGHI MONICA | 2009-04-16 | — | — | US | disclosed |
| US-20070161639-A1 | Hiv integrase inhibitors | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-07-12 | — | — | US | disclosed |
| US-20070161639-A1 | Hiv integrase inhibitors | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-07-12 | — | — | US | disclosed |
| US-20070161639-A1 | Hiv integrase inhibitors | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161639-A1 | Hiv integrase inhibitors | DPYD, DUT, TYMP | GAA 912/4885GRM2 3168/4885KCNH2 666/4885 |
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | TPMT, XDH, DPYD | GAA 271/4885GRM2 1314/4885KCNH2 4450/4885 |
| US-20090099168-A1 | HIV Integrase inhibitors | DPYD, DUT, QDPR | GAA 1323/4885GRM2 3764/4885KCNH2 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.